Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 103,468

Document Document Title
WO/2014/187879A3
The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) recepto...  
WO/2014/186878A1
Provided are methods and agents for depleting senescent cells endogenous to a subject, involving administering to the subject a binding agent that is selectively toxic to senescent cells in an amount effective to reduce the number of suc...  
WO/2014/190271A2  
WO/2014/187226A1
Disclosed are use of levorotary mefloquine in the preparation of a medication for preventing or treating neuropathic pain and a pharmaceutical composition comprising a therapeutically effective amount of levorotary mefloquine and a pharm...  
WO/2014/190139A1
The present invention relates to a use of composition comprising a glucose anti-metabolite and/or source of glucose anti-metabolite in a method of enhancing a positive affect and/or energetic arousal in a mammal.  
WO/2014/187879A2
The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) recepto...  
WO/2014/188197A1
This invention relates to the use of a very low dose of tacrolimus or a close structural analogue to treat a disease characterised by deposition of protein aggregates in neuronal cells. More particularly this invention relates to the use...  
WO/2014/184973A1
Provided is a transplantation adjuvant for neural progenitor cells, said transplantation adjuvant comprising valproic acid and/or zonisamide as active ingredient(s).  
WO/2014/184327A1
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazolesand -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 recept...  
WO/2014/186310A1
The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), w...  
WO/2014/183520A1
Provided are a thiophene miazines derivate with a general formula (I), a pharmaceutical salt thereof, a preparation method therefor, and an application for being used as a therapeutical agent for treating a cancer and particularly used a...  
WO/2014/186400A1
As follows from the Background section, above, there is a need in the art for improved methods for the treatment of mood and/or anxiety disorders. The present disclosure provides therapeutic agents and methods for treating mood (e.g., Ma...  
WO/2014/184275A1
The invention relates to 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to...  
WO/2014/183220A1
The present invention relates to a method of producing expandable cultured brain cells. The brain cells are neurotrophic factor (NTF) positive. The expandable cultured brain cells are obtained by culturing a biopsy obtained from the cort...  
WO/2014/183630A1
The present invention provides a compound as represented by formula I, which has a structure as follows: R1 and R2 are glycosyl, R3 is H, hydroxyl or methoxyl; R4 is hydroxyl or methoxyl; and R5 is H, hydroxyl or methoxyl. The present in...  
WO/2014/184234A1
A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 an...  
WO/2014/185470A1
The present invention addresses the problem of providing a method for producing a graft material, which has a high restoring effect on dysfunction caused by nerve damage, at a high efficiency and a high reproducibility. Provided are a me...  
WO/2014/185481A1
Provided is a cell membrane transport promoter for the selective 5-HT1A serotonin receptors. This cell membrane transport promoter for the selective 5-HT1A serotonin receptors contains as an active ingredient 8-[2-(2-pentyl-cyclopropylme...  
WO/2014/180229A1
Disclosed is a use of bionic recombinant high density lipoprotein (HDL) in the preparation of drugs for preventing and treating Alzheimer's disease. The bionic recombinant HDL consists of lipid and apoprotein. The apoprotein is one or mo...  
WO/2014/180238A1
The present invention discloses an antihypoxic pharmaceutical composition and application thereof. The pharmaceutical composition contains vinpocetine and L-carnitine or a derivative thereof and a pharmaceutically acceptable salt thereof...  
WO/2014/182051A1
The present invention relates to a composition comprising an ASM inhibitor as an active ingredient for preventing or treating degenerative neurological diseases. According to the present invention, when ASM is partially removed in an Alz...  
WO/2014/180165A1
Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D3 receptor, 5-HT1A receptor and 5-HT2A...  
WO/2014/180264A1
The invention relates to a stable organic amine salt of fosphenytoin and the preparation method and use thereof, the related organic amine salt of fosphenytoin having a structure of the general formula as shown in general formula (I), an...  
WO/2014/181840A1
Provided is an adhesive patch that, when adhered to the skin, has low skin irritancy while having ample adhesion to the skin, affords good transdermal permeation of rotigotine, and exhibits sufficient transdermal absorption. The adhesive...  
WO/2014/182260A2  
WO/2014/180305A1
The invention relates to a phenol derivative and the preparation method and use in medicine thereof, and in particular, relates to a phenol derivative as shown in the general formula (A), or stereoisomers, solvates, metabolites, prodrugs...  
WO/2014/180556A1
The present invention relates to arylpiperazines, and to the efficient treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition typically arises as a consequence of long-term treatment with L-DOPA therapy in P...  
WO/2014/181333A3
Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical f...  
WO/2014/181101A1
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as "2-acyl-4-oxy-1,2-dihydropyrrol-5-on...  
WO/2014/181280A1
The present invention relates to stable pharmaceutical composition of anxiolytic agents. Particularly, the present invention relates to stable pharmaceutical composition of Etifoxine and its pharmaceutically acceptable salts thereof. Mor...  
WO/2014/180321A1
The present invention provides a class of phloroglucinol derivatives, a preparation method thereof, a pharmaceutical composition comprising the compounds, and an application of these compounds in preparing medicine for preventing and/or ...  
WO/2014/181788A1
The present invention provides: a novel α-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the α-substituted glycineamide derivative or a pharmacologically acce...  
WO/2014/180327A1
The present invention relates to a phenol derivative, a method of preparing same, and a pharmaceutical application of same, and more particularly, the present invention relates to a compound shown by the general formula (I) or a stereois...  
WO/2014/177490A1
The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2014/177527A1
The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2014/177060A1
The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R 1, R 2, R 3, X 1, X 2, A and Cy variable in Formula (I-I) all have the mean...  
WO/2014/179551A1
A method and associated system of treating a plant material consisting essentially of the plant cannabis in order to extract cannabinoids in liquid form from the plant material. The method includes heating the plant material; drying the ...  
WO/2014/178892A1
Described herein is the use of sobetirome for the treatment of neurodegenerative disease involving demyelination or other abnormalities with oligodendrocyte function, including but not limited to X-linked adrenoleukodystrophy (X-ALD), mu...  
WO/2014/176632A1
In alternative embodiments, the invention provides compositions and methods for treating, ameliorating and preventing various disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where the microbi...  
WO/2014/177676A1
An effective dose of fenfluramine or its pharmaceutically acceptable salt for use in a method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome.  
WO/2014/176942A1
Disclosed is the use of an asparagus powder in medicines for the treatment of anxiety and depressive mental disorders, and in food and health foods, with the content of active ingredients contained in the asparagus powder being as follow...  
WO/2014/178803A1
The invention relates to a composition formed for use in the treatment of the alcohol addiction.  
WO/2014/178931A1
Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include admin...  
WO/2014/177977A1
The present invention is directed to a new class of triazine derivatives as described by formula (I) below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.  
WO/2014/177042A1
Provided in the present invention is a linker and a preparation method thereof, wherein one end of the linker may covalently link a small molecule compound and the like and the other end may specifically and covalently link a targeting s...  
WO/2014/178954A1
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using...  
WO/2014/177286A1
The invention relates to the use of biotin for treating X-linked adrenoleukodistrophy, in particular adrenomyeloneuropathy.  
WO/2014/177491A1
Title: New Solid Form of 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine Hydrobromide The present invention relates to 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine hydrobromide (vortioxetine hydrobromide,a drug for the treatment of ...  
WO/2014/177524A1
The present invention provides for pyrimidine compounds of Formula (I-I) and embodiments thereof. In Formula (I-I) in which R1, R2, R3, R4, R5, R6' m, n and the "het" ring are as described herein. Also provided are pharmaceutical composi...  
WO/2014/177127A1
The invention relates to an agent for the prophylaxis and/or treatment of HIV and other viral infections. The agent contains, in particular, at least one peptide with an amino acid sequence suitable for the prophylaxis of fibrilla associ...  

Matches 251 - 300 out of 103,468